Data Show “Super Bug” Surveillance System Based on OpGen’s Acuitas(R) Resistome Test Can Identify Potential Outbreaks in Hospitals and Improve Infection Control
October 12, 2015 08:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., Oct. 12, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a...
Melinta Therapeutics Presents Complete Delafloxacin Results from Phase 3 Study in Patients with Acute Bacterial Skin and Skin Structure Infections at ID Week
October 09, 2015 15:30 ET
|
Melinta Therapeutics
NEW HAVEN, CT and SAN DIEGO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced...
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
May 19, 2015 16:00 ET
|
Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative
impact of obesity on patients' recovery from acute bacterial skin
and skin structure...
Cempra Presenting Additional Data From the Phase 3 Oral Solithromycin Study in Community Acquired Bacterial Pneumonia at the American Thoracic Society Conference
May 19, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports First Quarter 2015 Financial Results and Provides Corporate Update
April 30, 2015 16:04 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 30, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report First Quarter 2015 Financial Results
April 23, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment
April 09, 2015 12:02 ET
|
Melinta Therapeutics
New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of
Health-Related Quality-of-Life (HRQL) in acute bacterial skin and
skin structure infection...
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital
February 09, 2015 08:00 ET
|
Melinta Therapeutics
New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a
$30 million growth capital debt financing agreement with Hercules
Technology Growth...
Cempra to Present at Three Upcoming Investor Conferences
February 03, 2015 08:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil
January 08, 2015 15:08 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the
largest pharmaceutical companies in Brazil, announced that...